ArticleJournal of neuro-oncology2016
Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Surgical Intervention in Very Elderly Patients with Spinal Ependymoma: A National Cancer Database Analysis.Cancers · 2026Article
- Primary intracranial myxopapillary ependymoma: two case reports and literature review.Frontiers in oncology · 2026Article
- Radiological analysis correlated with neurological outcomes following resection of myxopapillary ependymoma: patient series.Journal of neurosurgery. Case lessons · 2025Article
- Myxopapillary Ependymoma: A Case Report.Cureus · 2025Article
- The Many Faces of Myxopapillary Ependymomas.AJNR. American journal of neuroradiology · 2025Article
- Epidemiological characteristics of myxopapillary ependymoma and factors affecting overall survival: a SEER-based analysis.Translational cancer research · 2024Article
- Specifics of spinal neuropathology in the molecular age.Neuro-oncology advances · 2024Review
- Outcomes and Pattern of Care for Spinal Myxopapillary Ependymoma in the Modern Era-A Population-Based Observational Study.Cancers · 2024Article
- Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Frontiers in molecular neuroscience · 2024Review
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Ependymoma from Benign to Highly Aggressive Diseases: A Review.Advances and technical standards in neurosurgery · 2024Review
- Review
- Resection of a large thoracolumbar intradural ependymoma: a 2D operative video.Neurosurgical focus: Video · 2023Article
- Spinal ependymoma in adults: from molecular advances to new treatment perspectives.Frontiers in oncology · 2023Review
- Article
- Ependymomas.Pathologica · 2022Review
- Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.Neuro-oncology · 2022Article
- Major Features of the 2021 WHO Classification of CNS Tumors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Extra-Neural Metastases of Late Recurrent Myxopapillary Ependymoma to Left Lumbar Paravertebral Muscles: Case Report and Review of the Literature.Brain sciences · 2022Article
- Massive myxopapillary ependymoma of the gluteal cleft.ANZ journal of surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxopapillary ependymoma (MPE) is an exceedingly rare tumor histology. While surgery is clearly the treatment of choice, controversy exists regarding the role of adjuvant radiotherapy (RT). Using the Surveillence, epidemiology, and end results (SEER) database, we aimed to determine the epidemiology, prognostic factors, and treatment-related outcomes for MPE. A total of 773 cases were found in the SEER database. The incidence in the American population was found to be 1.00 per million person-years. On multivariate analysis, receipt of surgery (HR = 0.14, CI = 0.06-0.35, p < 0.001), receipt of RT (HR = 4.06, CI = 1.87-8.81, p < 0.001), age less than 30 (HR = 0.24, CI = 0.08-0.72, p = 0.01), and Caucasian race (HR = 0.37, CI = 0.13-0.996, p = 0.049) were statistically significant prognostic factors. The mean tumor size among those receiving RT (4.6 cm) was significantly larger than among those not receiving RT (3.2 cm, p = 0.0002). Those who lived in metropolitan areas were more likely to receive RT than those who did not. Given multiple previous studies show that RT improves PFS and the discrepancy in tumor size, selection bias is likely a significant contributor to the apparent negative impact of RT on OS. Regardless, surgery remains the most crucial aspect in the care of patients with MPE.
Indexed as
Identifiers
27306443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.